Press Release—Responsum Health to Recruit Participants for Aldeyra Therapeutics’ Atopic Dermatitis Clinical Trial

Responsum Health to Recruit Participants for Aldeyra Therapeutics’ Atopic Dermatitis Clinical Trial

A leading clinical-stage biotechnology company partners with Responsum Health to help bring symptom relief to people living with this chronic inflammatory condition.

[WASHINGTON, D.C., July 5, 2023] —Today, Responsum Health (Responsum), an innovative developer of personalized health knowledge apps and digital patient communities, announced a partnership with Aldeyra Therapeutics on a new project to provide patient recruitment services for The ADRO Trial: An Adaptive, 2-Part, Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Adults With Atopic Dermatitis.

Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory condition that causes the skin to become red, flaky, and itchy. The condition can be caused by a combination of internal and external factors. Itchy skin is a major symptom that can impact everyday life and cause sleep loss, anxiety, and depression. Chronic atopic dermatitis may require long-term use of medications to help control symptoms. Some medications may be inconvenient, expensive, and/or cause harmful side effects.

ADX-629 is a potential treatment option being researched for people with AD whose symptoms are not well-controlled by existing medications. ADX-629 may help improve symptoms related to atopic dermatitis by reducing inflammation. This clinical trial is being conducted to learn more about the safety of ADX-629 and to see if it improves symptoms in adults with atopic dermatitis. 

As part of its newest collaboration with Aldeyra, Responsum Health will utilize its dynamic, online patient engagement platforms to inform, identify, pre-screen, and connect pre-qualified patients to applicable clinical trial sites in the United States.

We’re excited about embarking on this newest project to help recruit patients for this important Phase 2 clinical trial, said Andrew Rosenberg, Founder and CEO of Responsum Health. Aldeyra is an innovative powerhouse in the pharmtech industry, and we value their continuing trust in us.

About Responsum Health

Responsum (Latin for “the answer”) is an innovative digital health technology company whose mission is to empower and support people who live with chronic conditions and who seek ways to live their best lives.

Responsum provides free, condition-specific patient engagement platforms and apps that monitor, search, and curate news articles, blog posts, and scientific papers from the Internet, then generate personalized Newsfeeds of article summaries vetted by partner patient groups and subject matter experts.

Responsum platforms also enable patients to organize their personal health data, find local patient support groups and services, participate in clinical trials, and share their lived experiences with peers in a moderated community chat.

Today, thousands of patients and caregivers rely on Responsum Health for their daily dose of news and education in areas as diverse as Long COVID, pulmonary fibrosis, chronic kidney disease, uterine fibroids, glaucoma, and menopause.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company devoted to developing innovative medicines to improve the lives of patients with immune-mediated diseases. Their approach is to create therapies that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. 

Aldeyra is the leader in the discovery and development of novel reactive aldehydes species (RASP) modulators as well as other candidates for retinal diseases. 


For more information about Responsum Health, please contact Jessica Finch at, or you can also visit our website at

Leave a Reply

Your email address will not be published. Required fields are marked *